Vaccination of renal cell cancer patients with TroVax (modified vaccinia Ankara delivering the tumor antigen 5T4) plus IFN{alpha}: A phase II trial
2008
3053 Background: The attenuated vaccinia virus, modified vaccinia Ankara (MVA) has been engineered to express the tumor antigen 5T4 (TroVax [T]). Approximately 90% of renal cell tumors overexpress ...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
4
Citations
NaN
KQI